Mostrar el registro sencillo del ítem
dc.contributor.author
Drebes, Julia
dc.contributor.author
Künz, Madeleine
dc.contributor.author
Pereira, Claudio Alejandro
dc.contributor.author
Betzel, Christian
dc.contributor.author
Wrenger, Carsten
dc.date.available
2017-07-13T19:53:08Z
dc.date.issued
2014-02
dc.identifier.citation
Drebes, Julia; Künz, Madeleine; Pereira, Claudio Alejandro; Betzel, Christian; Wrenger, Carsten; MRSA infections: from classical treatment to suicide drugs; Bentham Science Publishers; Current Medicinal Chemistry; 21; 15; 2-2014; 1809-1819
dc.identifier.issn
0929-8673
dc.identifier.uri
http://hdl.handle.net/11336/20403
dc.description.abstract
Infections caused by the methicillin-resistant Staphylococcus aureus (MRSA) are today a major burden in nosocomial disease control. The global trend shows an alarming increase of MRSA infections as well as multi-drug resistance (MDR). The problem is exacerbated by the fact that infections with community-associated (CA) MRSA strains showing increased virulence and fitness add to infections with multi-drug resistant hospital-associated (HA) MRSA. The toxicity of pathogens and limited effectiveness of available treatment have led to high mortality rates and vast expenses caused by prolonged hospitalization and usage of additional antibiotics. Recently approved drugs still have classical targets and upcoming resistance can be expected. In a new approach by targeting co-factor syntheses of bacteria, the drug target and the affected pathways are uncoupled. This novel strategy is based on the thought of a classical pro-drug which has to be metabolized before becoming toxic for the bacterium as a dysfunctional co-factor, named suicide drug. Ideally these metabolizing pathways are solely present in the bacterium and absent in the human host, such as vitamin biosyntheses. This mini-review discusses current ways of MRSA infection treatment using new approaches including suicide drugs targeting co-factor biosyntheses.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Bentham Science Publishers
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
B Vitamins
dc.subject
Co-Factor Starvation
dc.subject
Drug Discovery
dc.subject
Mrsa
dc.subject
Multi Drug Resistance
dc.subject
Pro-Drug
dc.subject
Suicide Drug
dc.subject.classification
Biología Celular, Microbiología
dc.subject.classification
Ciencias Biológicas
dc.subject.classification
CIENCIAS NATURALES Y EXACTAS
dc.title
MRSA infections: from classical treatment to suicide drugs
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2017-07-13T17:23:20Z
dc.identifier.eissn
1875-533X
dc.journal.volume
21
dc.journal.number
15
dc.journal.pagination
1809-1819
dc.journal.pais
Emiratos Árabes Unidos
dc.journal.ciudad
Sharjah
dc.description.fil
Fil: Drebes, Julia. Universitat Hamburg; Alemania
dc.description.fil
Fil: Künz, Madeleine. Universitat Hamburg; Alemania
dc.description.fil
Fil: Pereira, Claudio Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Médicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; Argentina
dc.description.fil
Fil: Betzel, Christian. Universitat Hamburg; Alemania
dc.description.fil
Fil: Wrenger, Carsten. Universidade de Sao Paulo; Brasil
dc.journal.title
Current Medicinal Chemistry
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/http://www.eurekaselect.com/118131/article
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.2174/0929867320666131119122520
Archivos asociados